Shares of Prothena PRTA tumbled 22.5% in after-hours trading on May 23 after it announced the discontinuation of the ...

Patients with metastatic colorectal cancer who were treated with a biweekly dose of trifluridine-tipiracil (TAS-102) saw ...

More than half of patients maintained minimal residual disease (MRD) negativity (10-5) with DARZALEX FASPRO® for 24 months or longer in the Phase 3 PERSEUS study Data from Phase 3 CEPHEUS study ...

How cancer patients relying on daratumumab feel physically before starting the therapy can predict how long they will live and how well they will respond to the anti-multiple myeloma (MM ...

in favor of the benefit-risk profile of single-agent DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) for the treatment of adult patients with high-risk smoldering multiple myeloma (HR-SMM).

Pieter Sonneveld, MD, PhD, professor of hematology and chair of the Erasmus MC Cancer Institute in Rotterdam, Netherlands, discussed the continued use of subcutaneous daratumumab following initial ...

The FDA is likely to approve the first treatment for smoldering multiple myeloma but pass on a new option relapsed/refractory DLBCL, after votes by its Oncologic Drugs Advisory Committee.

Forest plots of daratumumab OS efficacy (vs. therapies without daratumumab) according to (A) low- and (B) high-physical function. The study analyzed data from 1,804 patients enrolled in three ...

and monoclonal antibodies like daratumumab. Regimens like VCD and Dara-VTD are common, particularly among transplant-eligible patients. While early response rates are often strong, relapse remains ...

At ARVO 2025, in Salt Lake City, Utah, Dilsher Dhoot, MD, FASRS, and Mark Barakat, MD, talked about the PHOTON trial, 8 mg ...

How cancer patients feel physically before beginning treatment with daratumumab can predict how long they will live and how well they will respond to this multiple myeloma therapy, according to ...

AFFIRM-AL trial enrolled 207 newly diagnosed AL amyloidosis patients, dosing birtamimab every 28 ... and the use of daratumumab was allowed. Also Read: Roche-Prothena Partnered Mid-Stage Parkinson ...